Blenoxane: profile and news

ABVD Remains Best Treatment for Advanced Hodgkin’s Lymphoma Oct 21, 2005
The standard chemotherapy regimen for these patients has been ABVD: doxorubicin (Adriamycin®), bleomycin (Blenoxane®), Velban® (vinblastine), and ... - Cancer Consultants (press release),

Dr. Gaff's Column Sep 4, 2005
It may take months for this treatment to work. • Bleomycin (Blenoxane) halts the making of DNA in cells and viruses. Bleomycin ... - KPCnews.com,

Case Charging Nation's Largest Drug Companies of Defrauding ... Aug 18, 2005
...have received these drugs stand up and be counted." The prescription drugs mentioned in the complaint include: -- Alkeran -- Blenoxane -- Cytoxan -- Etopophos ... - PR Newswire (press release),

Spector, Roseman & Kodroff, PC Say Federal Judge Allows Consumers ... Aug 19, 2005
The prescription drugs mentioned in this complaint include: Alkeran, Blenoxane, Cytoxan, Etopophos, Kytril, Navelbine, Paraplatin, Procrit, Remicade, Rubex ... - Business Wire (press release),

Other information

Indication
For palliative treatment in the management of the following neoplasms; Malignant neoplasm (trachea, bronchus, lung); Squamous cell carcinoma; Lymphomas

Pharmacology
Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases). Bleomycin is indicated in the palliative treatment of squamous cell carcinoma, lymphomas, testicular carcinoma, alone or in combination with other drugs.

Mechanism Of Action
Although the exact mechanism of action of Bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.

Drug Category
Antimetabolites; Antibiotics; Antineoplastic Agents; ATC:L01DC01

Brand Names/Synonyms
BLEOMYCIN; BLM; Blenoxane; Bleo; Bleocin; Bleomicin; Bleomicina [INN-Spanish]; Bleomycin (USAN ); Bleomycin sulfate; Bleomycine [INN-French]; Bleomycins; Bleomycinum [INN-Latin]

Dosage Forms
Injection; POWDER FOR SOLUTION

Absorption
systemic absorption approximately 45%

Interactions
[an error occurred while processing this directive]

Chemical IUPAC Name
3-[[2-[2-[2-[2-[4-[2-[6-amino-2-[1-(2-amino-2-carbamoyl-ethyl)amino-2-carbamoyl-ethyl]-5-methyl-pyrimidin-4-yl]carbonylamino-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-3-(3H-imidazol-4-yl)propanoyl]amino-3-hydroxy-2-methyl-pentanoyl]amino-3-hydroxy-butanoyl]aminoethyl]-1,3-thiazol-4-yl]-1,3-thiazol-4-yl]carbonylamino]propyl-dimethyl-sulfonium

Chemical Formula
C55H84N17O21S3

Half Life
115 minutes

Drug Type
Approved Drug

# Accession No
APRD00453

CAS Registry Number
11056-06-7